SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights

On April 5, 2022 SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported a business update and overview of activity in the first quarter of 2022 (Press release, Sellas Life Sciences, APR 5, 2022, View Source [SID1234611451]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The first quarter of 2022 has been transformative for SELLAS as we have significantly enhanced our clinical pipeline with the in-license from GenFleet Therapeutics (Shanghai), Inc. ("GenFleet") of global rights outside of Greater China for GFH009, a highly selective small molecule cyclin-dependent kinase 9 ("CDK9") inhibitor. At the same time, we have continued to progress our lead asset, galinpepimut-S ("GPS"), which is currently being tested in clinical trials for acute myeloid leukemia ("AML"), malignant pleural mesothelioma ("MPM") and relapsed/refractory metastatic ovarian cancer," said Angelos M. Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS. "We also strengthened our balance sheet with the closing of a public offering, underwritten by SVB Leerink and Cantor, which will support the continued development of GPS and our ongoing and planned studies for GFH009. We view the addition of GFH009 as a strategic fit to our overall clinical development plans."

Dr. Stergiou continued, "GFH009 provides us with an opportunity to expand further into the market for AML therapeutics covering not only the maintenance phase of the disease, which is the indication being studied for GPS in the REGAL trial, but also active disease by combining GFH009 with venetoclax and azacitidine. GFH009 has shown a strong synergy with venetoclax in preclinical models, and we believe it has the potential to improve response to venetoclax or possibly convert resistance to venetoclax into a response. Furthermore, we have an opportunity with GFH009 to address additional indications and tumor types, including the very important pediatric market of soft tissue sarcomas – positive results from this program could ultimately provide the basis for a rare pediatric disease priority voucher. Additionally, GenFleet plans to conduct numerous Phase 2 clinical trials for hematological malignancies in China. The data generated by these trials will effectively help us to analyze and identify additional indications in which to launch pivotal studies in our own territories. This parallel development in different indications allows both companies to leverage a much broader body of both safety and efficacy data thus potentially significantly accelerating clinical development."

"As we continue to progress toward commercialization with GPS, we were thrilled to announce that Robert Francomano joined the SELLAS team in March as Chief Commercial Officer. Robert brings to SELLAS more than 25 years of biopharmaceutical experience, with the majority of time spent in the hematology/oncology therapeutic area, making him a strong addition to our management team," Dr. Stergiou concluded.

Pipeline Update:

Galinpepimut-S (GPS)

Phase 3 REGAL Study: The Company is continuing to activate and enroll patients in additional sites in the United States, Europe, and Asia. As has been the case with many of its peer companies, the Company has continued to observe that COVID-19 related delays have impacted its projected timeline for the REGAL study. Under the Company’s current planning assumptions, which take into account the Company’s best estimates of potential delays due to COVID-19 as well as input by its external statisticians and experts, the Company believes that enrollment for the REGAL study will be completed in late 2022 or early in the first quarter of 2023 and the planned interim analysis will occur by the end of the first half of 2023, provided that its statistical assumptions and assumptions regarding the impact of COVID-19 on the operations of clinical sites as well as the duration of the pandemic remain unchanged. Because this analysis is event driven, it may become available at a different time than currently expected.

Phase 1/2 GPS Study in Combination with Merck’s KEYTRUDA: In February 2022, the Company completed enrollment in the Phase 1/2 clinical trial of GPS in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in second or third line Wilms Tumor-1 (WT1)(+) relapsed or refractory metastatic ovarian cancer. Data from 15 patients will be examined by mid-2022, with final data analysis for all evaluable patients expected by the end of 2022.

Phase I GPS Study in China: In March 2022, an IND application to initiate the first clinical trial in China for GPS was approved by China’s National Medical Products Administration which triggered a milestone payment of $1 million, expected to be received by the Company in the second quarter of 2022. The IND, for a small Phase I clinical trial investigating safety, was submitted by SELLAS’ partner in China, 3D Medicines Inc. ("3D Medicines"). 3D Medicines expects to initiate the trial by mid-2022.
Manufacturing Improvements : In the fourth quarter of 2021, the Company’s contract manufacturer for GPS, Lyophilization Services of New England, Inc. (LSNE), manufactured a new regulatory standard drug product batch which entailed further process improvements, which were agreed upon by the FDA. The new manufacturing batch met all the release criteria and, to date, has shown favorable stability data on already known long-term conditions (-20°C) as well as newly accelerated conditions (5°C and 25°C). Both long-term and accelerated stability data are monitored to confirm that all drug product parameters are within the acceptance criteria. This optimized batch, based on the data to date, may ultimately allow for GPS to be stored in 5°C to 25°C conditions versus -20°C, which would be more optimal for supply chain and logistical reasons.

New Patent Allowance: In February 2022, the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering certain WT1-targeting peptides, in combination with other molecules such as other peptides and immunomodulating compounds, useful for treatment of WT1-expressing cancers. This patent application covering WT1-targeting peptides linked to other molecules, which complements the Company’s existing composition of matter patents covering GPS peptides (which expire in 2033 not including any potential extensions), is expected to grant later this year, and will have a patent term that extends to at least 2026.
GFH009

On March 31, 2022, the Company and GenFleet, a clinical-stage biotechnology company developing cutting-edge therapeutics in oncology and immunology, announced that the companies entered into an exclusive license agreement that grants rights to SELLAS for the development and commercialization of GFH009, a highly selective CDK9 inhibitor, across all therapeutic and diagnostic uses worldwide outside of Greater China (mainland China, Hong Kong, Macau and Taiwan).

GFH009 is currently in a Phase 1 clinical trial in China and the United States which is planned to enroll approximately 80 patients including an expansion part 2. The fourth of six doses is currently being studied in this dose-escalation study. To date, stable disease has been observed in three patients, and a bone marrow blast decreased from 40% to 20% was observed in one AML patient at the 9 mg dose level, which is the third of the six dose levels to be studied in the Phase 1 trial.

Following completion of the Phase 1 clinical trial and achievement of a maximum tolerated dose, SELLAS plans to commence a Phase 2 clinical trial of GFH009 in combination with venetoclax and azacitidine in AML patients with active disease, likely by the end of the second quarter of 2023. The Company also plans to commence a Phase 1/2 basket clinical trial of monotherapy GFH009 in pediatric soft tissue sarcomas, including Ewing’s sarcoma and rhabdomyosarcoma, in late 2022 or early 2023, which it expects to complete by the end of 2023. Positive results from this program could ultimately provide the basis for a rare pediatric disease priority voucher.
Nelipepimut-S (NPS)

Since 2018, based on promising data from a cohort of patients with triple negative breast cancer ("TNBC") from a Phase 2b investigator sponsored clinical trial of the combination of trastuzumab (Herceptin) plus NPS in HER2 low expressing breast cancer patients in the adjuvant setting, the Company has been seeking out-licensing opportunities for NPS focused on the future clinical development of NPS in TNBC. After extensive effort, the Company has concluded that continued efforts to outlicense NPS for further development for breast cancer alone are unlikely to result in a licensing transaction commensurate with the value of the asset which the Company believes is due to the changing market for breast cancer therapies, the scope, cost and timeline for a Phase 3 trial which would satisfy regulatory requirements for the TNBC indication and the failure, in 2016, by the Company’s predecessor, Galena, of the Phase 3 clinical trial of monotherapy NPS in breast cancer. The Company is continuing its out-licensing strategy focusing on the potential for NPS in other cancer indications.
Corporate Updates:

Underwritten Public Offering: On April 5, 2022, the Company closed an underwritten public offering of 4,629,630 shares of its common stock and accompanying warrants to purchase up to 4,629,630 shares of common stock at a combined public offering price of $5.40 per share and accompanying warrant providing gross proceeds to the Company of $25.0 million before deducting underwriting discounts and commissions and offering expenses. The warrants to purchase shares of common stock have an exercise price of $5.40 per share, are immediately exercisable and will expire five years from the date of issuance.

Cash Position: As of December 31, 2021, cash and cash equivalents totaled approximately $21.4 million.

Enhanced Leadership Team:

In March 2022, SELLAS appointed Robert Francomano as Chief Commercial Officer.

In January 2022, the Company promoted John Burns to Senior Vice President, Finance, and Chief Accounting Officer.

In the fourth quarter of 2021 and the first quarter of 2022, the Company added heads of manufacturing and quality control/quality assurance functions.

Settlement of Legacy Galena Litigations:

In February 2022, SELLAS received the final court approval of the settlement of securities litigation relating to the Company’s predecessor, Galena, marking the end to all litigation related to activities of Galena. In November 2021, SELLAS received final court approval of the settlement of three derivative suits relating to the securities litigation.
Webcast Information

The Company will host a shareholder update call tomorrow morning, Wednesday, April 6, 2022, at 8:30 a.m. eastern time featuring remarks by Angelos M. Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS.

To attend the live video webcast, please register or email KCSA Strategic Communications at [email protected].

Signify Health to Report First Quarter 2022 Earnings and Host Earnings Call on Thursday, May 5, 2022

On April 5, 2022 Signify Health, Inc. (NYSE: SGFY), a leading value-based healthcare platform enabled by advanced analytics, technology and nationwide healthcare networks, reported that it will release its financial results for the first quarter 2022 after the market closes on Wednesday, May 4, 2022, and will hold a conference call at 8:30am ET on Thursday, May 5, 2022 to discuss the results (Press release, Signify Health, APR 5, 2022, View Source [SID1234611450]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pre-registration is required for participation in the conference call. Please follow the link below to pre-register. After registering, you will be provided with your access details via email.

View Source

A webcast of the conference call will also be available live on the investor relations section of Signify Health’s website at View Source Please go to the website at least 15 minutes prior to the call to complete the registration process.

The webcast replay will be available through July 5, 2022 on Signify Health’s website at View Source

Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation

On April 5, 2022 Artios Pharma Limited (Artios), a clinical-stage biotech company pioneering the development of novel small molecule therapeutics that target the DNA damage response ("DDR") process in order to treat patients suffering from a broad range of cancers, reported that the development of its ataxia telangiectasia and Rad3-related ("ATR") Inhibitor, ART0380, has progressed into a Phase 1b dose expansion study targeting ATM deficient tumors (Press release, Artios Pharma, APR 5, 2022, View Source [SID1234611449]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Artios also announces a poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana featuring biomarker and pharmacokinetic data supporting the clinical dose selection of ART0380.

Dr. Niall Martin, Chief Executive Officer at Artios, said: "As a strong regulator of DNA repair, ATR inhibition can effectively suppress tumor growth across a broad range of cancers harboring genetic defects. However, durability and long-term use with first-generation ATR inhibitors has been limited by challenges with toxicity and tolerability. The pharmacokinetic profile of ART0380 has the potential to allow reliable and predictable dosing. We are highly encouraged with the initial dose escalation data which demonstrates that ART0380 is engaging the desired cancer pharmacodynamic targets, has a predictable and manageable safety profile and is clinically active in tumors predicted to be sensitive to ATR inhibition. We look forward to additional data from the dose expansion Phase 1b study targeting ATM deficient tumors in the first half of 2023."

Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology, Principal Investigator for the trial, said: "Following the successful completion of the intermittent monotherapy dose escalation, ART0380 has progressed to the dose expansion phase for evaluation in patients with cancers expressing low levels of the ATM protein. We also continue to explore the therapeutic potential of ART0380 in combination with gemcitabine and irinotecan."

Initial dose escalation evaluating intermittent dosing of ART0380

Key safety findings

An encouraging safety profile with no unexpected safety findings
Predictable, manageable, and reversible hematological toxicities expected from an ATR inhibitor
No evidence of off target toxicity
Key pharmacodynamic and pharmacokinetic findings

gH2AX DNA damage biomarker data supports dose-dependent target engagement in tumor cells but not normal mononuclear cells
Dose proportional increases in exposure with rapid absorption and elimination
Low interpatient variability

The global, open-label, multi-center, Phase 1/2a study is evaluating the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of ART0380 as a monotherapy or in combination with gemcitabine or irinotecan. The dose expansion portion of the trial will evaluate the potential of ART0380 monotherapy in patients who have cancers with low expression of ATM protein kinase, and the combination with gemcitabine in patients with high grade serous ovarian, primary peritoneal or fallopian tube carcinoma. The study is expected to enroll up to 180 patients and will be conducted at multiple oncology centers across the United States and Europe.

ART0380 is an inhibitor of ATR that is being developed as an oral anti-cancer agent for the treatment of participants with cancers that harbor defects in DNA repair and in combination with agents including those that cause DNA damage. ART0380 was originally in-licensed by Artios from The University of Texas MD Anderson Cancer Center and ShangPharma Innovation in 2019. The molecule was jointly developed as part of a collaboration between ShangPharma and MD Anderson’s Therapeutics Discovery Division.

AACR 2022 Poster Presentation Details

Abstract LB520 – A pharmacodynamic platform using liquid biopsy to support dose selection for the ATR inhibitor ART0380 (IACS-030380)

Date/Time: April 8, 2022, 12:00 PM – 1:00 PM

Session: OPO.ET05.01; Pharmacology, Pharmacogenetics, and Pharmacogenomics

Presenter: Manish Patel

Location: E-Poster Website

Entry into a Material Definitive Agreement

On April 5, 2022 Atreca, Inc. (the "Company") reported its entry into an Option and License Agreement (the "Option and License Agreement"), dated April 4, 2022, by and between the Company and Zymeworks Inc., a corporation organized and existing under the laws of British Columbia ("Zymeworks") (Filing, 8-K, Atreca, APR 5, 2022, View Source [SID1234611448]). Pursuant to the Option and License Agreement, the Company received from Zymeworks a non-exclusive, non-transferable, sublicensable, worldwide, royalty-free license under certain of Zymeworks’ patents and know-how (the "Zymeworks Intellectual Property") to perform preclinical research and development of antibody drug conjugates comprising antibodies owned or otherwise controlled by the Company conjugated to certain of Zymeworks’ proprietary ZymeLinkTM auristatin- or hemiasterlin-based linker-cytotoxins (each such antibody drug conjugate, an "ADC," and such license, the "Research License").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Zymeworks has also granted the Company an exclusive option (the "Commercial Option") to obtain an exclusive, transferable, sublicensable license for up to three (3) collaboration programs under the Zymeworks Intellectual Property to research, develop, manufacture and commercialize certain ADCs worldwide for therapeutic, prophylactic and diagnostic uses for all human and non-human indications, including all oncology indications. Each collaboration program involves the Company’s research and development directed to ADCs incorporating one (1) lead antibody sequence and up to two (2) backup antibody sequences nominated by the Company (each ADC comprising antibodies incorporating a lead sequence or backup sequence and arising from a collaboration program with respect to which the Company exercises the Commercial Option, a "Licensed Product"). If the Company exercises the Commercial Option, then the Company will have the exclusive right to develop, manufacture and commercialize Licensed Products worldwide and, with respect to each collaboration program, the Company will be required to use commercially reasonable efforts to develop and commercialize at least one Licensed Product and the Company will pay to Zymeworks an option exercise fee, and lump sum payments upon the achievement of certain development and regulatory milestones and commercial milestones. In addition, with respect to each Licensed Product, the Company will pay tiered royalties on net sales of Licensed Products at single-digit royalty rates.

Unless earlier terminated or extended under certain circumstances, the term of the Research License and the Commercial Option shall be two years from the effective date, with the Company having an option upon payment of a fee to Zymeworks to extend the term for an additional year (the "Research Program Term"). Unless earlier terminated, the term of the Option and License Agreement will continue on a Licensed Product-by-Licensed Product basis until the expiration of the Company’s royalty obligations for such Licensed Product. Notwithstanding the foregoing, if the Company does not nominate an antibody sequence to be the lead antibody sequence for any collaboration program during the Research Program Term, then the term of the Option and License Agreement will expire on the expiration of the Research Program Term.

The Option and License Agreement may be terminated by the Company, in its entirety or on a collaboration program-by-collaboration program basis, for convenience upon a certain number of days’ prior written notice to Zymeworks. The Option and License Agreement may be terminated by Zymeworks upon a certain number of days’ notice to the Company if the Company or certain related parties take certain actions to challenge Zymeworks’ patent rights and certain other conditions are not met. The Option and License Agreement may be terminated by either party upon a material breach by the other party (subject to prior written notice and a cure period) or upon certain insolvency events, including bankruptcy proceedings. The Option and License Agreement includes standard and customary provisions regarding, among other things, compliance with laws and regulations, confidentiality, intellectual property, representations and warranties, liability, indemnification, and insurance.

The foregoing description of the material terms of the Option and License Agreement is qualified in its entirety by reference to the full text of the Option and License Agreement, which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, to be filed with the Securities and Exchange Commission (the "SEC"). Pursuant to Item 601(b)(10)(iv) of Regulation S-K, the Company intends to redact from the filed copy of the Option and License Agreement certain information that is both (i) not material and (ii) is the type of information that the Company treats as private or confidential.

Heron Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference

On April 5, 2022 Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that company management will participate in a fireside chat at the 21st Annual Virtual Needham Healthcare Conference on Monday, April 11, 2022 at 8:00 am PT/11:00 am ET (Press release, Heron Therapeutics, APR 5, 2022, View Source [SID1234611447]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Company’s website at www.herontx.com in the Investor Resources section.